



Procedure Name: ClinicalTrials.gov	Number: SOP 17 v2.0
Subject: Clinical Research	Effective Date: February 01, 2023
Linked Policy: Clinical Research Operations & Compliance Policy	Revised Date: November 07, 2023

PURPOSE:

To establish the GW Medical Faculty Associates (MFA) procedure outlines the responsibilities of the research team members when using ClinicalTrials.gov

SCOPE:

This procedure applies to all research team members responsible for conducting clinical research at the MFA.

RESPONSIBILITY:

It is the responsibility of the Principal Investigator to ensure registration and results reporting are completed and updated, and in the timeframes required, by **FDAAA, NIH, CMS** and/or **ICMJE**. It is the Principal Investigator's responsibility to upload the required documents per the Final Rule for Clinical Trials Registration and Results Information Submission and the 2018 Common Rule. The PRS Admins within the Office of Clinical Research will reach out to the PI to register the trial after IRB approval and 6 months after study completion to remind the PI to report their results. The PRS Admins will also reach out to the PIs if there are any problems within the record that need to be addressed and if the trial needs to be updated.

PROCEDURES:

AGENCY REQUIREMENTS:

Studies registered on ClinicalTrials.gov must be registered through the GWUniversity organization account.

Principal Investigators are responsible to register clinical trials on ClinicalTrials.gov within required time frames, as follows:

- **GWU MFA:** We require the Principal Investigator to register their clinical trial on ClinicalTrials.gov BEFORE subject enrollment- preferably once the study is IRB approved.



Procedure Name: ClinicalTrials.gov	Number: SOP 17 v2.0
Subject: Clinical Research	Effective Date: February 01, 2023
Linked Policy: Clinical Research Operations & Compliance Policy	Revised Date: November 07, 2023

There are timeframes from governing bodies (below) that allow the PI to enter the trial after subject enrollment, but as best practice and GWU MFA policy, the trial should be entered into the system before any subject have been enrolled to ensure regulatory compliance and to avoid any deadlines. It is university policy that studies be entered once the IRB is approved or NO later than 21 days after the subject enrollment.

- **Under FDAAA:** The Principal Investigator must register and input required clinical trial information through the Protocol Registration System (PRS) on the ClinicalTrials.gov website no later than 21 days after enrollment of the first participant.
- **Under NIH:** The Principal Investigator must register and input required clinical trial information on the ClinicalTrials.gov website no later than 21 days after enrollment of the first participant
- **Under CMS:** The Principal Investigator must register and input required clinical trial information and obtain an NCT# at the ClinicalTrials.gov website before submitting claims for such services to CMS.
- **ICMJE:** The Principal Investigator must register with an ICMJE qualified publicly-accessible registry at or before the first patient is enrolled in the study as a condition for publication in a participating journal

UPDATING RECORDS:

Principal Investigators are responsible to update clinical trial records, review the record for accuracy and verify that data-entry occurs within the required time frames, as follows:

FDAAA, NIH, CMS and ICMJE require the following:

- Registration information must be updated no less than **once every six months;**
- Recruitment/enrollment status changes (such as suspending recruitment or enrollment closed) must be input **within 30 days of any change;**



Procedure Name: ClinicalTrials.gov	Number: SOP 17 v2.0
Subject: Clinical Research	Effective Date: February 01, 2023
Linked Policy: Clinical Research Operations & Compliance Policy	Revised Date: November 07, 2023

- Trial closure (regardless of the reason for closure—completion, low enrollment, etc.) must be input **within 30 days of trial closure.**

RESULTS REPORTING:

Principal investigators are responsible to ensure data-entry occurs within required timeframes, as follows:

- **FDAAA and NIH:** Aggregate results and adverse event reporting on ClinicalTrials.gov must occur within 12 months of the Primary Completion Date;
- **CMS and ICMJE:** If the study qualifies as a clinical trial under FDAAA or NIH, results and event reporting must occur within 12 months of the Primary Completion Date. If the study does not qualify as a clinical trial under FDAAA or NIH, results reporting is voluntary.

If the trial is covered by multiple applicable entities, registration and results reporting must occur within the timeframe set by the applicable entities, whichever is sooner.

OTHER CLINICALTRIALS.GOV SITE RESPONSIBILITIES:

Principal Investigators are responsible for the following:

As required per the Final Rule:

- Uploading the IRB-approved protocol and statistical analysis plan in a timely manner to ClinicalTrials.gov.
- Responding to registry reviewer requests for information or changes, as applicable, in a timely fashion.
- Submitting everything within the timeframes mentioned above



Procedure Name: ClinicalTrials.gov	Number: SOP 17 v2.0
Subject: Clinical Research	Effective Date: February 01, 2023
Linked Policy: Clinical Research Operations & Compliance Policy	Revised Date: November 07, 2023

TRANSFER OF PRINCIPAL INVESTIGATOR (PI) RESPONSIBILITIES:

During the course of a clinical trial, the PI may relocate to another institution or otherwise be unavailable to fulfill his/her role responsibilities as PI. Before leaving the University, the PI must work with the University PRS Admin to ensure an orderly transition of his/her responsibilities to the new PI at the University or to initiate transfer of the registry account/record(s) and PI responsibilities to the new institution.

If a clinical trial remains at the University and there are continuing registry reporting obligations without a named PI, then the PRS Admin must appoint a PI to serve and assume any remaining reporting obligations.

NOTE: If the PI fails to transfer the trial record and the trial is closed and results have been reported, the admin has the responsibility to try and contact the PI and if they do not ultimately respond, the university PRS Admin has the power to release the record.

TRANSFERRING A RECORD

- 1) GWUniversity should initiate transfers of studies to other institutions if they are receiving the record from another institution. Transfers of studies from GWUniversity to another institution should be initiated by the other institution. Per CT.gov:
 - a) Transfers must be coordinated between the organizations involved. If the receiving organization has Administrators, they are responsible for coordinating the transfer. For organizations without Administrators, the Responsible Party and Record Owners must coordinate the transfer.
 - b) Records in a Released state cannot be transferred.
- 2) Before requesting a transfer of the record to GWUniversity, make sure the record owner has a user account.
- 3) Request the transfer by emailing PRS Staff at Register@ClinicalTrials.gov.
 - a) PRS can be emailed directly from within the PRS system by click on the Contact ClinicalTrials.gov PRS link at the top right of the PRS page header.
 - b) CC the study PI, the CT.gov admin, and, if known, the lead Co-PI at the current record holder institution.
 - c) To complete a record transfer, PRS Staff must receive:
 - i) Confirmation from the receiving organization or Responsible Party that the record will be accepted (a copy of email confirmation is acceptable)



Procedure Name: ClinicalTrials.gov	Number: SOP 17 v2.0
Subject: Clinical Research	Effective Date: February 01, 2023
Linked Policy: Clinical Research Operations & Compliance Policy	Revised Date: November 07, 2023

- (1) If GWUniversity is receiving the record and initiating the request, this is not required.
- ii) Name of the receiving organization ([Institution CT.gov org name])
- iii) Username of the new Record Owner
- iv) NCT number of the record
- 4) Once the record is transferred, it will need to be updated.
 - a) Most areas requiring update will be flagged with an error.

COMPLIANCE WITH THE CLINICALTRIALS.GOV POLICY:

The University requires compliance with clinical trials registration and results reporting.

Review and Revision

The SOP Review Committee shall review this SOP every 2 years. This SOP may be reviewed more frequently if it does not reflect current operations.

REFERENCES:

- [FDAAA 801](#)
- [Clinical Trials Registration and Results Information Submission](#) (Final Rule)
- [NIH Elaboration Document of Responsible and Applicable Clinical Trial](#)
- NIH Policy & Compliance ClinicalTrials.gov and FDAAA: [FAQs](#)
- ClinicalTrials.gov website: www.clinicaltrials.gov
- [2018 Common Rule](#)
- 2018 Common Rule – [Clinical Trial Informed Consent Form Posting](#)
- [ICMJE FAQ](#)
- [CMS Medicare Clinical Trial Policies](#)
- Center for Medicare and Medicaid Services (CMS):
 - [Medicare Clinical Trial Policies](#)
 - [Routine Costs in Clinical Trials](#)
- [Final Rule](#) (42 CFR Part 11)
- GWU MFA ClinicalTrials.gov Policy